MYLA Diagnostic System Software Versions Recalled for Risk of False Negatives
BioMerieux MYLA diagnostic system software versions 4.7–4.8.2 may produce false negative results under certain conditions, potentially missing diagnoses. Affected units are being recalled worldwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II medical device recall addresses a risk for false negative results under certain conditions. The software failure could lead to missed diagnoses, representing significant potential for patient harm. However, no illnesses or injuries have been reported. This fits the 'High' severity category for risk-of-harm products where injury has not yet been reported.
Plain-English summary
BioMerieux SA is recalling MYLA diagnostic system software versions 4.7, 4.7.1, 4.8, 4.8.1, and 4.8.2, which are part of the VIRTUO diagnostic system. Approximately 542 units containing the affected software have been distributed.
Under certain conditions, the software may produce false negative results. This means the system could fail to detect a positive sample, potentially leading to missed diagnoses.
The affected software has been distributed worldwide, including throughout the United States and internationally to approximately 30 countries: Austria, Australia, Belgium, Canada, Switzerland, Chile, Colombia, Czech Republic, Denmark, Germany, Spain, Finland, France, United Kingdom, Guadeloupe, Hong Kong, Canary Islands, Ireland, India, Italy, Japan, South Korea, the Netherlands, Norway, Poland, Portugal, Sweden, Singapore, and South Africa.
Users of the affected VIRTUO system software should contact BioMerieux SA regarding this recall to obtain updated software versions and information about addressing this issue.
The recalled product
- Product
- MYLA Versions: 4.7, 4.7.1, 4.8, 4.8.1 and 4.8.2, part of the VIRTUO System
- Manufacturer
- BioMerieux SA
- Affected units
- 542
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- MYLA Software version 4.7
- 4.7.1
- 4.8
- 4.8.1 and 4.8.2
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · BioMerieux SA
See all →- HighMYLA Laboratory Software: Potential Test Result Alteration from Software Anomaly
FDA (Devices) · 2021-08-18
- ModerateBioMerieux NucliSENS Magnetic Extraction Reagents Recalled Due to Temperature Exposure
FDA (Devices) · 2018-10-31
- ModerateBioMerieux Recalls VIDAS FSH Assay Kits Due to Calibration Issues
FDA (Devices) · 2018-07-04
- ModerateBioMérieux Recalls VITEK 2 Gram Positive Susceptibility Cards Due to Temperature Excursion
FDA (Devices) · 2018-06-20
- ModerateBioMérieux PREVI Color Gram Reagents Recalled Due to Temperature Excursion
FDA (Devices) · 2018-06-20
Same hazard · false negative result
See all →- HighBioFire Respiratory Panel 2.1 Recalled for Increased False Negative Results
FDA (Devices) · 2026-08-19
- HighVITEK 2 AST-N447 Test Kit Potentially Returns False Resistant Results
FDA (Devices) · 2026-07-15
- HighLuminex VERIGENE Gram Negative Blood Culture Test Recalled
FDA (Devices) · 2025-06-11
- HighVERIGENE Clostridium difficile Nucleic Acid Test May Give False-Negative Results
FDA (Devices) · 2023-07-05
- HighMedical device test system recalled for decreased reactivity and false-negative results
FDA (Devices) · 2022-12-07